title: Comment on: Real-life effectiveness of canakinumab in cryoprin-associated periodic syndrome.
authors.affiliation: Immunology and Dermatology Novartis Pharma AG Basel, Global Medical Affairs, Switzerland.
authors.forename: Guido
authors.initials: G
authors.lastname: Junge
authors.affiliation: Immunology and Dermatology Novartis Pharma AG Basel, Global Medical Affairs, Switzerland uwe.machein@novartis.com.
authors.forename: Uwe
authors.initials: U
authors.lastname: Machein
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D056587:Cryopyrin-Associated Periodic Syndromes; D006801:Humans; D053583:Interleukin-1beta
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053583:Interleukin-1beta; C541220:canakinumab